Corrigendum: Efficacy and Safety of CAR-T Cell Products Axicabtagene Ciloleucel, Tisagenlecleucel, and Lisocabtagene Maraleucel for the Treatment of Hematologic Malignancies: A Systematic Review and Meta-Analysis

Bibliographic Details
Published in:	Frontiers in Oncology
Main Authors:	Jun Meng, XiaoQin Wu, Zhen Sun, RenDe Xun, MengSi Liu, Rui Hu, JianChao Huang
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2021-10-01
Subjects:	chimeric antigen receptor T-cell product CAR-T cell therapy immunotherapy lymphoma leukemia hematologic malignancy
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2021.768128/full

Similar Items

The Association Between Glucocorticoid Administration and the Risk of Impaired Efficacy of Axicabtagene Ciloleucel Treatment: A Systematic Review
by: Zhen Sun, et al.
Published: (2021-04-01)

Efficacy and safety of bendamustine for lymphodepletion before lisocabtagene maraleucel
by: Guido Ghilardi, et al.
Published: (2024-04-01)

P1385: DISTINCT RATES OF ICANS BUT SIMILAR CYTOKINE SIGNATURES BETWEEN TWO CD19-CAR T CELL THERAPIES: LISOCABTAGENE MARALEUCEL AND AXICABTAGENE CILOLEUCEL
by: Yusuf Rasheed, et al.
Published: (2023-08-01)

Lisocabtagene Maraleucel for Richter's Transformation—A Case Series
by: Courtney J. Smith, et al.
Published: (2025-04-01)

Tumor gene expression signatures associated with outcome in large B−cell lymphoma treated with CD19-directed CAR T−cell therapy (axicabtagene ciloleucel)
by: Yuan Tian, et al.
Published: (2025-02-01)

Comparison of axicabtagene ciloleucel and tisagenlecleucel patient CAR-T cell products by single-cell RNA sequencing
by: Xuefeng Wang, et al.
Published: (2025-07-01)

Real-world comparison of lisocabtagene maraleucel and axicabtagene ciloleucel in large B-cell lymphoma: an inverse probability of treatment weighting analysis with 3-year follow up
by: Andrew J. Portuguese, et al.
Published: (2025-03-01)

Axicabtagene ciloleucel compared to tisagenlecleucel for the treatment of aggressive B-cell lymphoma
by: Mi Kwon, et al.
Published: (2022-06-01)

Advances in CAR-NK cell therapy for hematological malignancies
by: Rui Yang, et al.
Published: (2024-06-01)

Exacerbations of Persistent Neurotoxicity following Axicabtagene Ciloleucel in a Patient with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Case Report
by: Graeme A. Fenton, et al.
Published: (2024-01-01)

P1381: DISTINCT CYTOKINE SIGNATURES OF IDECABTAGENE VICLEUCEL COMPARED TO AXICABTAGENE CILEUCEL AND LISOCABTAGENE MARALEUCEL
by: Abu-Sayeef Mirza, et al.
Published: (2023-08-01)

Venous Thromboembolism Risk in Hematological Malignancies Post-Chimeric Antigen Receptor T-Cell (CAR-T) Therapy: A Meta-Analysis of Phase 2 and Phase 3 Clinical Trials
by: Akshit Chitkara, et al.
Published: (2024-07-01)

New insights into CAR T-cell hematological toxicities: manifestations, mechanisms, and effective management strategies
by: Yuanyuan Yang, et al.
Published: (2024-11-01)

Recent findings on chimeric antigen receptor (CAR)-engineered immune cell therapy in solid tumors and hematological malignancies
by: Ali Keshavarz, et al.
Published: (2022-09-01)

CAR-engineered NK cells; a promising therapeutic option for treatment of hematological malignancies
by: Faroogh Marofi, et al.
Published: (2021-07-01)

Future perspectives on novel CAR-T therapeutics beyond CD19 and BCMA in onco-hematology
by: Alina Ershova, et al.
Published: (2025-07-01)

P1398: AXICABTAGENE CILOLEUCEL VERSUS TISAGENLECLEUCEL CAR-T CELLS IN RELAPSED OR REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA
by: Nico Gagelmann, et al.
Published: (2023-08-01)

Lisocabtagene maraleucel for treatment of relapsed and refractory primary mediastinal large B‐cell lymphoma in an adolescent patient
by: Dasom Lee, et al.
Published: (2024-02-01)

P1111: COMPARATIVE EFFICACY AND SAFETY OF TISAGENLECLEUCEL AND AXICABTAGENE CILOLEUCEL IN RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA
by: M. Dickinson, et al.
Published: (2022-06-01)

Editorial: Efficacy and safety of CAR-T cell therapy in hematologic malignancies
by: Marcos de Lima, et al.
Published: (2024-08-01)

Kymriah® (tisagenlecleucel) – An overview of the clinical development journey of the first approved CAR-T therapy
by: Rakesh Awasthi, et al.
Published: (2023-01-01)

Clinical, tumor, and product features associated with outcomes after axicabtagene ciloleucel therapy in follicular lymphoma
by: Soumya Poddar, et al.
Published: (2025-08-01)

Chimeric Antigen Receptor (CAR)-T Cell Therapy for Non-Hodgkin’s Lymphoma
by: Maria Giraudo, et al.
Published: (2024-03-01)

Cytokine release syndrome was an independent risk factor associated with hypoalbuminemia for patients with relapsed/refractory hematological malignancies after CAR-T cell therapy
by: Shuyi Ding, et al.
Published: (2023-11-01)

T cell senescence and CAR-T cell exhaustion in hematological malignancies
by: Dimitri Kasakovski, et al.
Published: (2018-07-01)

A Pharmacovigilance Study on the Safety of Axicabtagene Ciloleucel Based on Spontaneous Reports from the EudraVigilance Database
by: Concetta Rafaniello, et al.
Published: (2023-08-01)

Efficacy and side effects of anti‐CD19 CAR T‐cell therapy in patients with relapsed/refractory gastrointestinal lymphoma
by: Yi Li Jiang, et al.
Published: (2024-02-01)

CAR-T cell therapy for hematological malignancies: History, status and promise
by: Chao Wang, et al.
Published: (2023-11-01)

Matching-adjusted indirect comparison of efficacy and safety of lisocabtagene maraleucel and mosunetuzumab for the treatment of third-line or later relapsed or refractory follicular lymphoma
by: Loretta J. Nastoupil, et al.
Published: (2025-03-01)

Real-World Experiences of CAR T-Cell Therapy for Large B-Cell Lymphoma: How Similar Are They to the Prospective Studies?
by: Kevin Tang, et al.
Published: (2021-08-01)

Characterization of the input material quality for the production of tisagenlecleucel by multiparameter flow cytometry and its relation to the clinical outcome
by: Martin Štach, et al.
Published: (2023-04-01)

CAR-T cell combination therapy: the next revolution in cancer treatment
by: Maysoon Al-Haideri, et al.
Published: (2022-11-01)

Chimeric Antigen Receptor T Cell Therapy in Hematology
by: Pınar Ataca, et al.
Published: (2015-11-01)

A single center retrospective study on real world CAR T-cell therapy: focus on early hematological toxicity
by: Vadim Lesan, et al.
Published: (2024-11-01)

Grading of cytokine release syndrome associated with the CAR T cell therapy tisagenlecleucel
by: David Porter, et al.
Published: (2018-03-01)

Impact of Age on Early CAR T‐Cell Therapy Toxicity: A Propensity Score Matching Analysis
by: Jia Yi Tan, et al.
Published: (2025-11-01)

Chimeric antigen receptor T (CAR‐T) cells: Novel cell therapy for hematological malignancies
by: Samane Abbasi, et al.
Published: (2023-04-01)

Risk analysis of cardiovascular toxicity in patients with lymphoma treated with CD19 CAR T cells
by: Yang Liu, et al.
Published: (2025-01-01)

CAR-T Cells/-NK Cells in Cancer Immunotherapy and the Potential of MSC to Enhance Its Efficacy: A Review
by: Ler Yie Chan, et al.
Published: (2022-03-01)

Axicabtagene Ciloleucel in the Management of Follicular Lymphoma: Current Perspectives on Clinical Utility, Patient Selection and Reported Outcomes
by: Mohty R, et al.
Published: (2023-04-01)